ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.

(Alaric DeArment)

Merck & Co.’s initial Phase II/III waveLINE-003 data for zilovertamab vedotin (zilo-V) in diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology meeting in Chicago raised some questions from the presentation’s discussant about the small number of patients treated to date and the fact that they were not very heavily pretreated.

Key Takeaways
  • Data from Merck’s Phase II/III study of zilo-V in DLBCL presented at ASCO showed improvements in overall response and complete response rates when added to...

The data presented on 30 May were from the first part of a two-part trial that compared zilo-V combined with rituximab (Roche’s Rituxan and biosimilars), gemcitabine and oxaliplatin (R-GemOx) against...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ASCO

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

More from Therapy Areas

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.